Cytovia Therapeutics, Inc. and Cellectis announced that they have expanded their collaboration of TALEN? gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovia?s joint venture entity, CytoLynx Therapeutics. The amended financial terms include an equity stake totaling $20 million in Cytovia stock as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis is developing custom TALEN?, which Cytovia uses to edit iPSCs. Cytovia is responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and is conducting the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license under the patent rights over which Cellectis has the control in this field, including in China, enabling Cytovia to modify NK cells to address multiple gene-targets for therapeutic use in several cancer indications.